U.S. venture capital firms have deployed $412.7 billion year-to-date through 2026, the largest aggregate in the asset class's history. The capital is not distributing evenly. Seed and early-stage rounds are receiving the smallest share of total deployment in a decade, while late-stage and growth equity absorb the overwhelming majority of inflows.

The data confirms what limited partners suspected in Q4 2025: megafunds are writing larger checks into fewer companies, compressing the number of funded startups while inflating valuations at the top. Seed deal count is down 31% year-over-year, and Series A deployment has contracted 22% by dollar volume. Late-stage rounds—Series C and beyond—now represent 68% of total capital deployed, up from 52% in 2023. The median late-stage check size has risen to $87 million, a 40% increase since 2024. Meanwhile, the median seed round sits at $2.1 million, effectively flat for three years.

This bifurcation rewrites the venture formation playbook. Startups that cannot reach product-market fit with minimal external capital now face a funding desert between angel checks and institutional Series A. The traditional 18-month runway from seed to A has stretched to 26 months on average, forcing founders to either bootstrap longer or accept punitive dilution in bridge rounds. GPs with sub-$500 million funds report allocation pressure: their LPs are redirecting commitments to larger platforms with perceived access to breakout late-stage opportunities, leaving smaller managers scrambling for re-ups.

The concentration also signals a shift in LP behavior. Pension funds and endowments, bruised by the 2022–2023 markdowns, are now underwriting fewer managers and demanding co-investment rights in flagship deals. This creates a feedback loop: megafunds can offer LP co-invest, smaller funds cannot, so capital flows further upmarket. The result is a venture market that increasingly resembles private equity—large checks, operational due diligence, and a thinning pipeline of early bets. Family offices and high-net-worth allocators who historically accessed venture through diversified fund portfolios now face a choice: concentrate with the top decile or accept that their smaller commitments buy exposure to a structurally underfunded cohort.

Allocators should monitor Q2 2026 fund formation data, expected mid-May, to gauge whether emerging managers can close target fund sizes or face down-rounds on their own capital raising. The May NVCA quarterly report will provide granular stage breakdowns; any stabilization in Series A deal count would indicate the market is finding a new clearing price for risk. Private secondaries volume in venture-backed equity is another tell—if founders and early employees begin selling at steep discounts, it confirms the early-stage bridge has collapsed.

The $412.7 billion figure is a record by aggregate measure, but the denominator—number of companies funded—has contracted to its lowest level since 2019. Capital is abundant. Access is not.